Inavolisib
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Inavolisib, sold under the brand name Itovebi by Genentech, a member of the Roche group, is an anti-cancer medication used for the treatment of breast cancer. It is an inhibitor and degrader of mutated phosphatidylinositol 3-kinase (PI3K) alpha (PIK3CA). The most common adverse reactions include gastrointestinal disorders, high blood glucose, and infections. Inavolisib was approved for medical use in the United States in October 2024.
Inavolisib, sold under the brand name Itovebi by Genentech, a member of the Roche group, is an anti-cancer medication used for the treatment of breast cancer. It is an inhibitor and degrader of mutated phosphatidylinositol 3-kinase (PI3K) alpha (PIK3CA). The most common adverse reactions include gastrointestinal disorders, high blood glucose, and infections. Inavolisib was approved for medical use in the United States in October 2024.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1329208293 under CC BY-SA 4.0; modifications have been made.